Dosing Protocols for BPC-157 and TB-500

Introduction

Every dose on this page comes from user forums or vendor guides. As of October 2026, neither BPC-157 nor TB-500 has a human dose-finding study. For how the two differ biologically, see how BPC-157 and TB-500 work.

BPC-157 Dosing

Standard Dosing Range

Users describe roughly three tiers:

• Conservative: 200-250 mcg per day
• Moderate: 250-500 mcg per day (the most commonly reported)
• Aggressive: 500-750 mcg per day; some report 1-2 mg for injuries

The only published human dosing is a 2025 IV pilot: two adults received 10 mg, then 20 mg, with no adverse events reported.

Administration Methods

Timing Considerations

• Split protocols use morning and evening doses
• Reported durations of 4-12 weeks come from vendor and community guidance, not trials

TB-500 Dosing

TB-500 is a 7-amino-acid fragment of thymosin beta-4. As of October 2026, FDA says it has found no human exposure data for it, and users often aren't sure which molecule their vial holds.

Loading Phase (Weeks 1-6)

Vendor guidance describes:

• Standard: 2.0-2.5 mg twice weekly
• Total weekly dose: 4-5 mg
• Stated purpose: building tissue levels (no human data)

Forum users report a wider spread: 2-5 mg twice weekly, or 0.5-2 mg daily or every other day.

Maintenance Phase (After Loading)

Community guides describe:

• Standard: 2.0-2.5 mg once weekly
• Or: 1.0-1.25 mg twice weekly
• Duration: until the user feels recovered

Vendor guidance, including this site's product listing, describes monthly maintenance doses after the loading phase instead. Neither schedule has been tested in people.

Administration

• Users mostly report subcutaneous injection of vials reconstituted with bacteriostatic water, stored refrigerated
• The claim that site doesn't matter because TB-500 is "systemic" has no human absorption data behind it

Combined Protocol Example

This schedule mirrors community guides. The only human data on the pairing is an uncontrolled 2021 series in which 14 of 16 knee-pain patients reported relief.

Reconstitution Guidelines

Example math, not a dose recommendation:

BPC-157

• 5mg vial with 2ml bacteriostatic water
• Concentration: 2,500 mcg/ml
• 10 units on a U-100 insulin syringe = 250 mcg

TB-500

• 5mg vial with 2ml bacteriostatic water
• Concentration: 2,500 mcg/ml
• 100 units (1ml) = 2.5 mg

Safety Notes

• Community advice is to start low; no study has tested titration
• Users report early fatigue, low mood and injection-site reactions, often when combining both
• In rats and dogs, BPC-157 caused no tissue changes through 6 weeks; nothing longer has been studied
• Gray-market vials aren't made to drug standards, so the labeled dose may be wrong

What we still don't know

As of October 2026, a small Phase 1 trial of daily subcutaneous BPC-157 after rotator cuff surgery is registered but not yet recruiting. Nothing similar exists for TB-500. For how users adapt these schedules by injury, see injury recovery applications.

Comparison table

More on rules in legal status and regulatory considerations.